The Requirement for and Changing Composition of the Activating Protein-1 Transcription Factor during Differentiation of Human Leukemia HL60 Cells Induced by 1,25-Dihydroxyvitamin D3
Open Access
- 15 April 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (8) , 4402-4409
- https://doi.org/10.1158/0008-5472.can-05-3109
Abstract
The activating protein-1 (AP-1) transcription factor complex is a heterogeneous entity, composed in mammalian cells of dimers chosen from a group of at least eight proteins belonging to three families: jun, fos, and activating transcription factor (ATF). The AP-1 complexes participate in diverse biological processes that include cell proliferation, survival, and differentiation. These seemingly contrasting functions have been attributed to the intensity and duration of the signals provided by AP-1, but the biological consequences of changing composition of the AP-1 complex have not been fully explored. Here, we show that functional AP-1 is required for 1,25-dihydroxyvitamin D3 (1,25D)-induced monocytic differentiation, and that the composition of the AP-1 protein complex that binds TRE, its cognate DNA element, changes as cells differentiate. In HL60 cells in an early stage of differentiation, the principal AP-1 components detected by gel shift analysis include c-jun, ATF-2, fos-B, fra-1, and fra-2. In cells with a more established monocytic phenotype, the demonstrable AP-1 components are c-jun, ATF-2, jun-B, and fos-B. Following the addition of 1 nmol/L of 1,25D, the cellular content of each of these four proteins markedly increased in a sustained manner, whereas the increases in c-fos, fra-1, fra-2, and jun-D were minimal, if any. Small increases in mRNA levels encoding all AP-1 component proteins, except c-fos, were also noted. These findings provide a basis for the previously found participation of the c-Jun N-terminal kinase pathway in 1,25D-induced differentiation of myeloid leukemia cells, and direct attention to jun-B and fos-B as new cellular therapeutic targets, that may promote replicative quiescence associated with differentiation of malignant cells. (Cancer Res 2006; 66(8): 4202-9)Keywords
This publication has 54 references indexed in Scilit:
- Regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1α,25-dihydroxy Vitamin D3 and dietary Ca2+The Journal of Steroid Biochemistry and Molecular Biology, 2004
- Enhancement by other compounds of the anti-cancer activity of vitamin D3 and its analogsExperimental Cell Research, 2004
- Jun N‐terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25‐dihydroxyvitamin D3Journal of Cellular Biochemistry, 2003
- Role of MAP Kinases in the 1,25-Dihydroxyvitamin D3-induced Transactivation of the Rat Cytochrome P450C24 (CYP24) PromoterJournal of Biological Chemistry, 2002
- The p38 and JNK Pathways Cooperate to trans-Activate Vitamin D Receptor via c-Jun/AP-1 and Sensitize Human Breast Cancer Cells to Vitamin D3-induced Growth InhibitionJournal of Biological Chemistry, 2002
- AP-1 as a regulator of cell life and deathNature Cell Biology, 2002
- Activation of the c-fos enhancer by the Erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sitesOncogene, 2000
- Differentiation-Related Mechanisms Which Suppress DNA ReplicationExperimental Cell Research, 1999
- Selective Expression of fos- and jun-Related Genes during Osteoblast Proliferation and DifferentiationExperimental Cell Research, 1995
- New Concepts of Vitamin D FunctionsaAnnals of the New York Academy of Sciences, 1992